Measuring patient-reported outcomes in advanced gastric cancer

ecancermedicalscience

Volumn 7, Issue 1, 2013, Pages

  Xu, Jianming ^a   Evans, T R Jeffry ^b   Coon, Cheryl ^c,d   Copley Merriman, Kati ^c   Su, Yun ^e  

^a Beijing 307 Hospital   (China)

^b UNIVERSITY OF GLASGOW   (United Kingdom)

^c RTI HEALTH SOLUTIONS   (United States)

^d ADELPHI REAL WORLD   (United Kingdom)

^e BRISTOL MYERS SQUIBB   (United States)

Author keywords

Digestive signs; Gastric cancer; Outcome measures; Patient outcome assessment; Symptoms

Indexed keywords

CISPLATIN; DOCETAXEL; FLUOROURACIL; FOLINIC ACID; IRINOTECAN;

ABDOMINAL PAIN; ADVANCED CANCER; ARTICLE; ASIA; CANCER PROGNOSIS; CLINICAL ASSESSMENT TOOL; CLINICAL TRIAL; DISTANT METASTASIS; DYSPHAGIA; EATING; HUMAN; INTERVIEW; LIVER METASTASIS; LUNG METASTASIS; OUTCOME ASSESSMENT; PREVALENCE; PSYCHOMETRY; QUALITY OF LIFE; QUESTIONNAIRE; SELF REPORT; SHORT FORM 36; STOMACH CANCER; SYMPTOM; VALIDITY;

EID: 84885576600     PISSN: None     EISSN: 17546605     Source Type: Journal    
DOI: 10.3332/ecancer.2013.351     Document Type: Article

References (42)

1. Kelley JR and Duggan JM (2003) Gastric cancer epidemiology and risk factors J Clin Epidemiol 56 1-9 DOI: 10.1016/S0895- 4356(02)00534-6 PMID: 12589864
2. Blot WJ et al (1991) Rising incidence of adenocarcinoma of the esophagus and gastric cardia JAMA 265 1287-9 DOI: 10.1001/ jama.1991.03460100089030 PMID: 1995976
3. National Comprehensive Cancer Network (2012) Clinical practice guidelines in oncology: gastric cancer Version 2 Available at: http:// www.nccn.org/professionals/physician-gls/f-guidelines.asp#site (registration required). Accessed August 23 2012
4. International Agency for Research on Cancer (2008) Cancer fact sheet: stomach cancer incidence, mortality and prevalence worldwide in 2008. http://globocan.iarc.fr/factsheet.asp. Accessed March 22 2012
5. Bowrey DJ et al (2006) Use of alarm symptoms to select dyspeptics for endoscopy causes patients with curable esophagogastric cancer to be overlooked Surg Endosc 20(11) 1725-8 DOI: 10.1007/s00464-005-0679-3 PMID: 17024539
6. Hosseini SN et al (2007) Delay in diagnosis and treatment of gastric cancer: from the beginning of symptoms to surgery-an Iranian study Turk J Gastroenterol 18(2) 77-81 PMID: 17602354
7. Maconi G, Manes G and Porro GB (2008) Role of symptoms in diagnosis and outcome of gastric cancer World J Gastroenterol 14(8) 1149-55 DOI: 10.3748/wjg.14.1149 PMID: 18300338 PMCID: 2690660
8. McLoughlin JM (2004) Adenocarcinoma of the stomach: a review Proc (Bayl Univ Med Cent) 17 391-9 PMCID: 1200678
9. Murad AM et al (1993) Modified therapy with 5-fluorouracil, doxorubicin, and methotrexate in advanced gastric cancer Cancer 72 37-41 DOI: 10.1002/1097-0142(19930701)72:1<37::AID-CNCR2820720109>3.0.CO;2-P PMID: 8508427
10. Pyrhonen S et al (1995) Randomised comparison of fluorouracil, epidoxorubicin and methotrexate (FEMTX) plus supportive care with supportive care alone in patients with non-resectable gastric cancer Br J Cancer 71 587-91 DOI: 10.1038/bjc.1995.114 PMID: 7533517 PMCID: 2033628
11. Glimelius B et al (1997) Randomized comparison between chemotherapy plus best supportive care with best supportive care in advanced gastric cancer Ann Oncol 8 163-8 DOI: 10.1023/A:1008243606668 PMID: 9093725
12. Webb A et al (1997) Randomized trial comparing epirubicin, cisplatin, and fluorouracil versus fluorouracil, doxorubicin, and methotrexate in advanced esophagogastric cancer J Clin Oncol 15 261-7 PMID: 8996151
13. van Cutsem E et al (2006) Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V25 study group J Clin Oncol 24(31) 4991-7 DOI: 10.1200/ JCO.2006.06.8429 PMID: 17075117
14. Cunningham D et al (2008) Capecitabine and oxaliplatin for advanced esophagogastric cancer New Engl J Med 358 36-46 DOI: 10.1056/NEJMoa073149 PMID: 18172173
15. Bang YJ et al (2010) Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2- positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial Lancet 376 687-97 DOI: 10.1016/S0140-6736(10)61121-X PMID: 20728210
16. Bezjak A et al (2001) Oncologists' use of quality of life information: results of a survey of Eastern Cooperative Oncology Group physicians Qual Life Res 10(1) 1-13 DOI: 10.1023/A:1016692804023 PMID: 11508471
17. Gondek K et al (2007) Current status of patient-reported outcomes in industry-sponsored oncology clinical trials and product labels J Clin Oncol 25(32) 5087-93 DOI: 10.1200/JCO.2007.11.3845 PMID: 17991926
18. Chau I et al (2004) Multivariate prognostic factor analysis in locally advanced and metastatic esophago-gastric cancer- pooled analysis from three multicenter, randomized, controlled trials using individual patient data J Clin Oncol 22(12) 2395-403 DOI: 10.1200/JCO.2004.08.154 PMID: 15197201
19. Bickenbach K and Strong VE (2012) Comparisons of gastric cancer treatments: East vs. West J Gastric Cancer 12(2) 55-62 DOI: 10.5230/jgc.2012.12. 2.55 PMID: 22792517 PMCID: 3392325
20. Verdeccchia A et al (2003) Comparison of stomach incidence and survival in four continents Eur J Cancer 39 1603-9 DOI: 10.1016/S0959-8049(03)00360-5
21. Kim J et al (2010) Race and ethniciy correlate with survival in patients with gastric adenocarcinoma Ann Oncol 21 152-60 DOI: 10.1093/annonc/mdp290
22. Al-Refaie WB et al (2008) The impact of ethnicity on the presentation and prognosis of patients with gastric adenocarcinoma. Results from the National Cancer Data Base Cancer 113(3) 461-9 DOI: 10.1002/cncr.23572 PMID: 18553367
23. Hsu C et al (2012) Geographic difference in safety and efficacy of systemic chemotherapy for advanced gastric or gastroesophageal carcinoma: a met-analysis and meta-regression Gastric Cancer 15 265-80 DOI: 10.1007/s10120-011-0106-5 PMID: 22576708
24. Blazeby JM et al (2004) Clinical and psychometric validation of a questionnaire module, the EORTC QLQ-STO22, to assess quality of life in patients with gastric cancer Eur J Cancer 40 2260-8 DOI: 10.1016/j.ejca.2004.05.023 PMID: 15454251
25. Garland SN et al (2011) Prospective evaluation of the reliability, validity, and minimally important difference of the functional assessment of cancer therapy-gastric (FACT-Ga) quality-of-life instrument Cancer 117(6) 1302-12 DOI: 10.1002/cncr.25556
26. Wang XS et al (2010) Validation and application of a module of the M.D. Anderson Symptom Inventory for measuring multiple symptoms in patients with gastrointestinal cancer (the MDASI-GI) Cancer 116 2053-63 DOI: 10.1002/cncr.24920 PMID: 20166216
27. Oñate-Ocaña LF et al (2009) Validation of the Mexican Spanish version of the EORTC C30 and STO22 questionnaires for the evaluation of health-related quality of life in patients with gastric cancer Ann Surg Oncol 16(1) 88-95 DOI: 10.1245/s10434-008- 0175-9
28. US Department of Health and Human Services, Food and Drug Administration (2009) Guidance for Industry: patient-reported outcome measures-use in medical product development to support labeling claims http://www.fda.gov/downloads/ Drugs/GuidanceComplianceRegulatoryInformation/ Guidances/UCM193282.pdf. Accessed 20 March 2012
29. Vickery CW et al (2001) EORTC Quality of Life Group. Development of an EORTC disease-specific quality of life module for use in patients with gastric cancer Eur J Cancer 37(8) 966-71 DOI: 10.1016/S0959-8049(00)00417-2 PMID: 11334720
30. Eremenco SL, Cashy J and Webster K (2004) FACT-Gastric: a new international measure of QOL in gastric cancer. 2004 ASCO annual meeting proceedings (post-meeting edition) J Clin Oncol 22(14S, July 15 Suppl) 8123
31. Aaronson NK et al (1993) The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology J Natl Cancer Inst 85(5) 365-76 DOI: 10.1093/jnci/85.5.365 PMID: 8433390
32. Cella DF et al (1993) The Functional Assessment of Cancer Therapy scale: development and validation of the general measure J Clin Oncol 11(3) 570-9 PMID: 8445433
33. Morita S et al (2008) The domain structure of the EORTC QLQ-STO22 supported by Japanese validation data Psychooncology 17(5) 474-9 DOI: 10.1002/pon.1256
34. Sadighi S et al (2009) Quality of life in patients with gastric cancer: translation and psychometric evaluation of the Iranian version of EORTC QLQ-STO22 BMC Cancer 9 305 DOI: 10.1186/1471-2407-9-305 PMID: 19715606 PMCID: 2741487
35. European Organization for Research and Treatment of Cancer (EORTC). Validated modules by language. June 2011. http://groups. eortc.be/qol/eortc- modules Accessed 27 July 2011.
36. McDowell I (2006) Measuring Health: A Guide to Rating Scales and Questionnaires 3rd edn (New York: Oxford University Press)
37. MDAnderson.org. The MD Anderson Symptom Inventory (MDASI). 2012. http://www.mdanderson.org/education-and-research/departments- programs-and-labs/departments-and-divisions/symptom-research/ symptom-assessment-tools/m-d-anderson-symptom-inventory. html. Accessed 13 August 2012
38. Bonnetain F et al (2005) Longitudinal quality of life study in patients with metastatic gastric cancer: analysis modalities and clinical applicability of QoL in randomized phase II trial in a digestive oncology Gastroenterol Clin Biol 29(11) 1113-24 DOI: 10.1016/S0399-8320(05)82175-X
39. Ajani JA et al (2007) Quality of life with docetaxel plus cisplatin and fluorouracil compared with cisplatin and fluorouracil from a phase III trial for advanced gastric or gastroesophageal adenocarcinoma: the V-325 Study Group J Clin Oncol 25(22) 3210-16 DOI: 10.1200/JCO.2006.08.3956 PMID: 17664468
40. Curran D et al (2009) Quality of life of palliative chemotherapy naive patients with advanced adenocarcinoma of the stomach or esophagogastric junction treated with irinotecan combined with 5-fluorouracil and folinic acid: results of a randomised phase III trial Qual Life Res 18(7) 853-61 DOI: 10.1007/s11136-009-9493-z PMID: 19568958 PMCID: 2724642
41. Park SH et al (2006) Paclitaxel versus docetaxel for advanced gastric cancer: a randomized phase II trial in combination with infusional 5-fluorouracil Anticancer Drugs 17 225-9 DOI: 10.1097/00001813-200602000-00015 PMID: 16428942
42. Wild D et al (2005) Principles of good practice for the translation and cultural adaptation process for patient-reported outcomes (PRO) measures: report of the ISPOR task force for translation and cultural adaptation Value Health 8 94-104 DOI: 10.1111/j.1524-4733.2005.04054.x PMID: 15804318